**2024 Interstitial Lung Disease Symposium:**

***Understanding Genetic Contributors to Interstitial Lung Disease***

**Stanford Division of Pulmonary, Allergy, and Critical Care**

**Stanford University School of Medicine**

**September 14, 2024**

Familial ILD: Current State and Future Directions - *Christine Kim Garcia, MD, PhD*

Adegunsoye, A., Newton, C. A., Oldham, J. M., Ley, B., Lee, C. T., Linderholm, A. L., Chung, J. H., Garcia,

N., Zhang, D., Vij, R., Guzy, R., Jablonski, R., Bag, R., Voogt, R. S., Ma, S. F., Sperling, A. I., Raghu, G., Martinez, F. J., Strek, M. E., Wolters, P. J., … Noth, I. (2023). Telomere length associates with chronological age and mortality across racially diverse pulmonary fibrosis cohorts. *Nature communications*, *14*(1), 1489. <https://doi.org/10.1038/s41467-023-37193-6>

Alder, J. K., Stanley, S. E., Wagner, C. L., Hamilton, M., Hanumanthu, V. S., & Armanios, M. (2015). Exome

sequencing identifies mutant TINF2 in a family with pulmonary fibrosis. *Chest*, *147*(5), 1361–1368. <https://doi.org/10.1378/chest.14-1947>

Allen, R. J., Guillen-Guio, B., Croot, E., Kraven, L. M., Moss, S., Stewart, I., Jenkins, R. G., & Wain, L. V.

(2022). Genetic overlap between idiopathic pulmonary fibrosis and COVID-19. *The European respiratory journal*, *60*(1), 2103132. <https://doi.org/10.1183/13993003.03132-2021>

Armanios, M. Y., Chen, J. J., Cogan, J. D., Alder, J. K., Ingersoll, R. G., Markin, C., Lawson, W. E., Xie, M.,

Vulto, I., Phillips, J. A., 3rd, Lansdorp, P. M., Greider, C. W., & Loyd, J. E. (2007). Telomerase mutations in families with idiopathic pulmonary fibrosis. *The New England journal of medicine*, *356*(13), 1317–1326. <https://doi.org/10.1056/NEJMoa066157>

Cogan, J. D., Kropski, J. A., Zhao, M., Mitchell, D. B., Rives, L., Markin, C., Garnett, E. T., Montgomery, K.

H., Mason, W. R., McKean, D. F., Powers, J., Murphy, E., Olson, L. M., Choi, L., Cheng, D. S., Blue, E. M., Young, L. R., Lancaster, L. H., Steele, M. P., Brown, K. K., … Blackwell, T. S. (2015). Rare variants in RTEL1 are associated with familial interstitial pneumonia. *American journal of respiratory and critical care medicine*, *191*(6), 646–655. <https://doi.org/10.1164/rccm.201408-1510OC>

Cronkhite, J. T., Xing, C., Raghu, G., Chin, K. M., Torres, F., Rosenblatt, R. L., & Garcia, C. K. (2008).

Telomere shortening in familial and sporadic pulmonary fibrosis. *American journal of respiratory and critical care medicine*, *178*(7), 729–737. <https://doi.org/10.1164/rccm.200804-550OC>

Dai, J., Cai, H., Li, H., Zhuang, Y., Min, H., Wen, Y., Yang, J., Gao, Q., Shi, Y., & Yi, L. (2015). Association

between telomere length and survival in patients with idiopathic pulmonary fibrosis. *Respirology (Carlton, Vic.)*, *20*(6), 947–952. <https://doi.org/10.1111/resp.12566>

Diaz de Leon, A., Cronkhite, J. T., Katzenstein, A. L., Godwin, J. D., Raghu, G., Glazer, C. S., Rosenblatt, R.

L., Girod, C. E., Garrity, E. R., Xing, C., & Garcia, C. K. (2010). Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations. *PloS one*, *5*(5), e10680. <https://doi.org/10.1371/journal.pone.0010680>

Dressen, A., Abbas, A. R., Cabanski, C., Reeder, J., Ramalingam, T. R., Neighbors, M., Bhangale, T. R.,

Brauer, M. J., Hunkapiller, J., Reeder, J., Mukhyala, K., Cuenco, K., Tom, J., Cowgill, A., Vogel, J., Forrest, W. F., Collard, H. R., Wolters, P. J., Kropski, J. A., Lancaster, L. H., … Yaspan, B. L. (2018). Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study. *The Lancet. Respiratory medicine*, *6*(8), 603–614. <https://doi.org/10.1016/S2213-2600(18)30135-8>

Duckworth, A., Gibbons, M. A., Allen, R. J., Almond, H., Beaumont, R. N., Wood, A. R., Lunnon, K.,

Lindsay, M. A., Wain, L. V., Tyrrell, J., & Scotton, C. J. (2021). Telomere length and risk of idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease: a mendelian randomisation study. *The Lancet. Respiratory medicine*, *9*(3), 285–294. <https://doi.org/10.1016/S2213-2600(20)30364-7>

Fingerlin, T. E., Murphy, E., Zhang, W., Peljto, A. L., Brown, K. K., Steele, M. P., Loyd, J. E., Cosgrove, G. P.,

Lynch, D., Groshong, S., Collard, H. R., Wolters, P. J., Bradford, W. Z., Kossen, K., Seiwert, S. D., du Bois, R. M., Garcia, C. K., Devine, M. S., Gudmundsson, G., Isaksson, H. J., … Schwartz, D. A. (2013). Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. *Nature genetics*, *45*(6), 613–620. <https://doi.org/10.1038/ng.2609>

Hobbs, B. D., Putman, R. K., Araki, T., Nishino, M., Gudmundsson, G., Gudnason, V., Eiriksdottir, G., Zilhao

Nogueira, N. R., Dupuis, J., Xu, H., O'Connor, G. T., Manichaikul, A., Nguyen, J., Podolanczuk, A. J., Madahar, P., Rotter, J. I., Lederer, D. J., Barr, R. G., Rich, S. S., Ampleford, E. J., … Hunninghake, G. M. (2019). Overlap of Genetic Risk between Interstitial Lung Abnormalities and Idiopathic Pulmonary Fibrosis. *American journal of respiratory and critical care medicine*, *200*(11), 1402–1413. <https://doi.org/10.1164/rccm.201903-0511OC>

Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu, G., Anstrom, K. J., King, T. E., Jr, Lasky, J.

A., & Martinez, F. J. (2012). Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. *The New England journal of medicine*, *366*(21), 1968–1977. <https://doi.org/10.1056/NEJMoa1113354>

Kropski, J. A., Mitchell, D. B., Markin, C., Polosukhin, V. V., Choi, L., Johnson, J. E., Lawson, W. E., Phillips, J.

A., 3rd, Cogan, J. D., Blackwell, T. S., & Loyd, J. E. (2014). A novel dyskerin (DKC1) mutation is associated with familial interstitial pneumonia. *Chest*, *146*(1), e1–e7. <https://doi.org/10.1378/chest.13-2224>

Ley, B., & Collard, H. R. (2013). Epidemiology of idiopathic pulmonary fibrosis. *Clinical epidemiology*, *5*,

483–492. <https://doi.org/10.2147/CLEP.S54815>

Ley, B., Newton, C. A., Arnould, I., Elicker, B. M., Henry, T. S., Vittinghoff, E., Golden, J. A., Jones, K. D.,

Batra, K., Torrealba, J., Garcia, C. K., & Wolters, P. J. (2017). The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis: an observational cohort-control study. *The Lancet. Respiratory medicine*, *5*(8), 639–647. <https://doi.org/10.1016/S2213-2600(17)30216-3>

Maryoung, L., Yue, Y., Young, A., Newton, C. A., Barba, C., van Oers, N. S., Wang, R. C., & Garcia, C. K.

(2017). Somatic mutations in telomerase promoter counterbalance germline loss-of-function mutations. *The Journal of clinical investigation*, *127*(3), 982–986. <https://doi.org/10.1172/JCI91161>

McGroder, C. F., Salvatore, M. M., D'Souza, B. M., Hoffman, E. A., Baldwin, M. R., & Garcia, C. K. (2024).

Improved pulmonary function and exercise tolerance despite persistent pulmonary fibrosis over 1 year after severe COVID-19 infection. *Thorax*, *79*(5), 472–475. <https://doi.org/10.1136/thorax-2023-220370>

Moore, C., Blumhagen, R. Z., Yang, I. V., Walts, A., Powers, J., Walker, T., Bishop, M., Russell, P., Vestal, B.,

Cardwell, J., Markin, C. R., Mathai, S. K., Schwarz, M. I., Steele, M. P., Lee, J., Brown, K. K., Loyd, J. E., Crapo, J. D., Silverman, E. K., Cho, M. H., … Schwartz, D. A. (2019). Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. *American journal of respiratory and critical care medicine*, *200*(2), 199–208. <https://doi.org/10.1164/rccm.201810-1891OC>

Newton, C. A., Batra, K., Torrealba, J., Kozlitina, J., Glazer, C. S., Aravena, C., Meyer, K., Raghu, G., Collard,

H. R., & Garcia, C. K. (2016). Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive. *The European respiratory journal*, *48*(6), 1710–1720. <https://doi.org/10.1183/13993003.00308-2016>

Newton, C. A., Kozlitina, J., Lines, J. R., Kaza, V., Torres, F., & Garcia, C. K. (2017). Telomere length in

patients with pulmonary fibrosis associated with chronic lung allograft dysfunction and post-lung transplantation survival. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*, *36*(8), 845–853. <https://doi.org/10.1016/j.healun.2017.02.005>

Newton, C. A., Oldham, J. M., Ley, B., Anand, V., Adegunsoye, A., Liu, G., Batra, K., Torrealba, J., Kozlitina,

J., Glazer, C., Strek, M. E., Wolters, P. J., Noth, I., & Garcia, C. K. (2019). Telomere length and genetic variant associations with interstitial lung disease progression and survival. *The European respiratory journal*, *53*(4), 1801641. <https://doi.org/10.1183/13993003.01641-2018>

Newton, C. A., Zhang, D., Oldham, J. M., Kozlitina, J., Ma, S. F., Martinez, F. J., Raghu, G., Noth, I., &

Garcia, C. K. (2019). Telomere Length and Use of Immunosuppressive Medications in Idiopathic Pulmonary Fibrosis. *American journal of respiratory and critical care medicine*, *200*(3), 336–347. <https://doi.org/10.1164/rccm.201809-1646OC>

Partanen, J. J., Häppölä, P., Zhou, W., Lehisto, A. A., Ainola, M., Sutinen, E., Allen, R. J., Stockwell, A. D.,

Leavy, O. C., Oldham, J. M., Guillen-Guio, B., Cox, N. J., Hirbo, J. B., Schwartz, D. A., Fingerlin, T. E., Flores, C., Noth, I., Yaspan, B. L., Jenkins, R. G., Wain, L. V., … Koskela, J. T. (2022). Leveraging global multi-ancestry meta-analysis in the study of idiopathic pulmonary fibrosis genetics. *Cell genomics*, *2*(10), 100181. <https://doi.org/10.1016/j.xgen.2022.100181>

Petrovski, S., Todd, J. L., Durheim, M. T., Wang, Q., Chien, J. W., Kelly, F. L., Frankel, C., Mebane, C. M.,

Ren, Z., Bridgers, J., Urban, T. J., Malone, C. D., Finlen Copeland, A., Brinkley, C., Allen, A. S., O'Riordan, T., McHutchison, J. G., Palmer, S. M., & Goldstein, D. B. (2017). An Exome Sequencing Study to Assess the Role of Rare Genetic Variation in Pulmonary Fibrosis. *American journal of respiratory and critical care medicine*, *196*(1), 82–93. <https://doi.org/10.1164/rccm.201610-2088OC>

Planas-Cerezales, L., Arias-Salgado, E. G., Buendia-Roldán, I., Montes-Worboys, A., López, C. E.,

Vicens-Zygmunt, V., Hernaiz, P. L., Sanuy, R. L., Leiro-Fernandez, V., Vilarnau, E. B., Llinás, E. S., Sargatal, J. D., Abellón, R. P., Selman, M., & Molina-Molina, M. (2019). Predictive factors and prognostic effect of telomere shortening in pulmonary fibrosis. *Respirology (Carlton, Vic.)*, *24*(2), 146–153. <https://doi.org/10.1111/resp.13423>

Popescu, I., Mannem, H., Winters, S. A., Hoji, A., Silveira, F., McNally, E., Pipeling, M. R., Lendermon, E.

A., Morrell, M. R., Pilewski, J. M., Hanumanthu, V. S., Zhang, Y., Gulati, S., Shah, P. D., Iasella, C. J., Ensor, C. R., Armanios, M., & McDyer, J. F. (2019). Impaired Cytomegalovirus Immunity in Idiopathic Pulmonary Fibrosis Lung Transplant Recipients with Short Telomeres. *American journal of respiratory and critical care medicine*, *199*(3), 362–376. <https://doi.org/10.1164/rccm.201805-0825OC>

Seibold, M. A., Wise, A. L., Speer, M. C., Steele, M. P., Brown, K. K., Loyd, J. E., Fingerlin, T. E., Zhang, W.,

Gudmundsson, G., Groshong, S. D., Evans, C. M., Garantziotis, S., Adler, K. B., Dickey, B. F., du Bois, R. M., Yang, I. V., Herron, A., Kervitsky, D., Talbert, J. L., Markin, C., … Schwartz, D. A. (2011). A common MUC5B promoter polymorphism and pulmonary fibrosis. *The New England journal of medicine*, *364*(16), 1503–1512. <https://doi.org/10.1056/NEJMoa1013660>

Snetselaar, R., van Batenburg, A. A., van Oosterhout, M. F. M., Kazemier, K. M., Roothaan, S. M., Peeters,

T., van der Vis, J. J., Goldschmeding, R., Grutters, J. C., & van Moorsel, C. H. M. (2017). Short telomere length in IPF lung associates with fibrotic lesions and predicts survival. *PloS one*, *12*(12), e0189467. <https://doi.org/10.1371/journal.pone.0189467>

Stanley, S. E., Gable, D. L., Wagner, C. L., Carlile, T. M., Hanumanthu, V. S., Podlevsky, J. D., Khalil, S. E.,

DeZern, A. E., Rojas-Duran, M. F., Applegate, C. D., Alder, J. K., Parry, E. M., Gilbert, W. V., & Armanios, M. (2016). Loss-of-function mutations in the RNA biogenesis factor NAF1 predispose to pulmonary fibrosis-emphysema. *Science translational medicine*, *8*(351), 351ra107. <https://doi.org/10.1126/scitranslmed.aaf7837>

Stuart, B. D., Choi, J., Zaidi, S., Xing, C., Holohan, B., Chen, R., Choi, M., Dharwadkar, P., Torres, F., Girod,

C. E., Weissler, J., Fitzgerald, J., Kershaw, C., Klesney-Tait, J., Mageto, Y., Shay, J. W., Ji, W., Bilguvar, K., Mane, S., Lifton, R. P., … Garcia, C. K. (2015). Exome sequencing links mutations in PARN and RTEL1 with familial pulmonary fibrosis and telomere shortening. *Nature genetics*, *47*(5), 512–517. <https://doi.org/10.1038/ng.3278>

Stuart, B. D., Lee, J. S., Kozlitina, J., Noth, I., Devine, M. S., Glazer, C. S., Torres, F., Kaza, V., Girod, C. E.,

Jones, K. D., Elicker, B. M., Ma, S. F., Vij, R., Collard, H. R., Wolters, P. J., & Garcia, C. K. (2014). Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis: an observational cohort study with independent validation. *The Lancet. Respiratory medicine*, *2*(7), 557–565. <https://doi.org/10.1016/S2213-2600(14)70124-9>

Tsakiri, K. D., Cronkhite, J. T., Kuan, P. J., Xing, C., Raghu, G., Weissler, J. C., Rosenblatt, R. L., Shay, J. W., &

Garcia, C. K. (2007). Adult-onset pulmonary fibrosis caused by mutations in telomerase. *Proceedings of the National Academy of Sciences of the United States of America*, *104*(18), 7552–7557. <https://doi.org/10.1073/pnas.0701009104>

Zhang, D., Adegunsoye, A., Oldham, J. M., Kozlitina, J., Garcia, N., Poonawalla, M., Strykowski, R.,

Linderholm, A. L., Ley, B., Ma, S. F., Noth, I., Strek, M. E., Wolters, P. J., Garcia, C. K., & Newton, C. A. (2023). Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease. *The European respiratory journal*, *62*(5), 2300441. <https://doi.org/10.1183/13993003.00441-2023>

Zhang, D., Eckhardt, C. M., McGroder, C., Benesh, S., Porcelli, J., Depender, C., Bogyo, K., Westrich, J.,

Thomas-Wilson, A., Jobanputra, V., & Garcia, C. K. (2024). Clinical Impact of Telomere Length Testing for Interstitial Lung Disease. *Chest*, S0012-3692(24)00808-0. Advance online publication. <https://doi.org/10.1016/j.chest.2024.06.006>

Zhang, D., Povysil, G., Kobeissy, P. H., Li, Q., Wang, B., Amelotte, M., Jaouadi, H., Newton, C. A., Maher, T.

M., Molyneaux, P. L., Noth, I., Martinez, F. J., Raghu, G., Todd, J. L., Palmer, S. M., Haefliger, C., Platt, A., Petrovski, S., Garcia, J. A., Goldstein, D. B., … Garcia, C. K. (2022). Rare and Common Variants in *KIF15* Contribute to Genetic Risk of Idiopathic Pulmonary Fibrosis. *American journal of respiratory and critical care medicine*, *206*(1), 56–69. <https://doi.org/10.1164/rccm.202110-2439OC>

Radiology of Familial ILD - *Ann Noi Chi Leung, MD*

Cecchini, M. J., Tarmey, T., Ferreira, A., Mangaonkar, A. A., Ferrer, A., Patnaik, M. M., Wylam, M. E.,

Jenkins, S. M., Spears, G. M., Yi, E. S., Hartman, T. E., Scott, J. P., & Roden, A. C. (2021). Pathology, Radiology, and Genetics of Interstitial Lung Disease in Patients With Shortened Telomeres. *The American journal of surgical pathology*, *45*(7), 871–884. <https://doi.org/10.1097/PAS.0000000000001725>

Lee, H. Y., Seo, J. B., Steele, M. P., Schwarz, M. I., Brown, K. K., Loyd, J. E., Talbert, J. L., Schwartz, D. A., &

Lynch, D. A. (2012). High-resolution CT scan findings in familial interstitial pneumonia do not conform to those of idiopathic interstitial pneumonia. *Chest*, *142*(6), 1577–1583. <https://doi.org/10.1378/chest.11-2812>

Raghu, G., Remy-Jardin, M., Richeldi, L., Thomson, C. C., Inoue, Y., Johkoh, T., Kreuter, M., Lynch, D. A.,

Maher, T. M., Martinez, F. J., Molina-Molina, M., Myers, J. L., Nicholson, A. G., Ryerson, C. J., Strek, M. E., Troy, L. K., Wijsenbeek, M., Mammen, M. J., Hossain, T., Bissell, B. D., … Wilson, K. C. (2022). Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *American journal of respiratory and critical care medicine*, *205*(9), e18–e47. <https://doi.org/10.1164/rccm.202202-0399ST>

What genetics of ILD tells us about lung biology and vice-versa - *Tushar Jasubhai Desai, MD*

Armanios, M. Y., Chen, J. J., Cogan, J. D., Alder, J. K., Ingersoll, R. G., Markin, C., Lawson, W. E., Xie, M.,

Vulto, I., Phillips, J. A., 3rd, Lansdorp, P. M., Greider, C. W., & Loyd, J. E. (2007). Telomerase mutations in families with idiopathic pulmonary fibrosis. *The New England journal of medicine*, *356*(13), 1317–1326. <https://doi.org/10.1056/NEJMoa066157>

Desai, T. J., Brownfield, D. G., & Krasnow, M. A. (2014). Alveolar progenitor and stem cells in lung

development, renewal and cancer. *Nature*, *507*(7491), 190–194. <https://doi.org/10.1038/nature12930>

Gough, H. G. (1956). *California Psychological Inventory*. Consulting Psychologists Press.

Haschek, W. M., & Witschi, H. (1979). Pulmonary fibrosis--a possible mechanism. *Toxicology and applied*

*pharmacology*, *51*(3), 475–487. <https://doi.org/10.1016/0041-008x(79)90372-7>

Juul, N. H., Stockman, C. A., & Desai, T. J. (2020). Niche Cells and Signals that Regulate Lung Alveolar

Stem Cells In Vivo. *Cold Spring Harbor perspectives in biology*, *12*(12), a035717. <https://doi.org/10.1101/cshperspect.a035717>

Logan, C. Y., & Desai, T. J. (2015). Keeping it together: Pulmonary alveoli are maintained by a hierarchy of

cellular programs. *BioEssays : news and reviews in molecular, cellular and developmental biology*, *37*(9), 1028–1037. <https://doi.org/10.1002/bies.201500031>

Nabhan, A. N., Brownfield, D. G., Harbury, P. B., Krasnow, M. A., & Desai, T. J. (2018). Single-cell Wnt

signaling niches maintain stemness of alveolar type 2 cells. *Science (New York, N.Y.)*, *359*(6380), 1118–1123. <https://doi.org/10.1126/science.aam6603>

Seibold, M. A., Wise, A. L., Speer, M. C., Steele, M. P., Brown, K. K., Loyd, J. E., Fingerlin, T. E., Zhang, W.,

Gudmundsson, G., Groshong, S. D., Evans, C. M., Garantziotis, S., Adler, K. B., Dickey, B. F., du Bois, R. M., Yang, I. V., Herron, A., Kervitsky, D., Talbert, J. L., Markin, C., … Schwartz, D. A. (2011). A common MUC5B promoter polymorphism and pulmonary fibrosis. *The New England journal of medicine*, *364*(16), 1503–1512. <https://doi.org/10.1056/NEJMoa1013660>

Developing a drug treatment for a genetic telomeropathy - *Yan Wang, PhD*

Armanios, M. Y., Chen, J. J., Cogan, J. D., Alder, J. K., Ingersoll, R. G., Markin, C., Lawson, W. E., Xie, M.,

Vulto, I., Phillips, J. A., 3rd, Lansdorp, P. M., Greider, C. W., & Loyd, J. E. (2007). Telomerase mutations in families with idiopathic pulmonary fibrosis. *The New England journal of medicine*, *356*(13), 1317–1326. <https://doi.org/10.1056/NEJMoa066157>

Borie, R., Kannengiesser, C., Sicre de Fontbrune, F., Gouya, L., Nathan, N., & Crestani, B. (2017).

Management of suspected monogenic lung fibrosis in a specialised centre. *European respiratory review : an official journal of the European Respiratory Society*, *26*(144), 160122. <https://doi.org/10.1183/16000617.0122-2016>

Chen, L., Roake, C. M., Freund, A., Batista, P. J., Tian, S., Yin, Y. A., Gajera, C. R., Lin, S., Lee, B., Pech, M. F.,

Venteicher, A. S., Das, R., Chang, H. Y., & Artandi, S. E. (2018). An Activity Switch in Human Telomerase Based on RNA Conformation and Shaped by TCAB1. *Cell*, *174*(1), 218–230.e13. <https://doi.org/10.1016/j.cell.2018.04.039>

Hoffman-La Roche. (2017). A Study to Investigate the Safety, Tolerability, Pharmacokinetics and

Pharmacodynamics of RO7020322 Following Oral Administration in Health Participants and Chronic Hepatitis B Patients. *ClinicalTrials.gov, Hoffman-La Roche*. <https://clinicaltrials.gov/study/NCT02604355>

Hwang, N., Sun, L., Noe, D., Lam, P. Y. S., Zhou, T., Block, T. M., & Du, Y. (2021). Hepatoselective

Dihydroquinolizinone Bis-acids for HBsAg mRNA Degradation. *ACS medicinal chemistry letters*, *12*(7), 1130–1136. <https://doi.org/10.1021/acsmedchemlett.1c00228>

Nagpal, N., Wang, J., Zeng, J., Lo, E., Moon, D. H., Luk, K., Braun, R. O., Burroughs, L. M., Keel, S. B., Reilly,

C., Lindsley, R. C., Wolfe, S. A., Tai, A. K., Cahan, P., Bauer, D. E., Fong, Y. W., & Agarwal, S. (2020). Small-Molecule PAPD5 Inhibitors Restore Telomerase Activity in Patient Stem Cells. *Cell stem cell*, *26*(6), 896–909.e8. <https://doi.org/10.1016/j.stem.2020.03.016>

Roake, C. M., Chen, L., Chakravarthy, A. L., Ferrell, J. E., Jr, Raffa, G. D., & Artandi, S. E. (2019). Disruption

of Telomerase RNA Maturation Kinetics Precipitates Disease. *Molecular cell*, *74*(4), 688–700.e3. <https://doi.org/10.1016/j.molcel.2019.02.033>

Stuart, B. D., Choi, J., Zaidi, S., Xing, C., Holohan, B., Chen, R., Choi, M., Dharwadkar, P., Torres, F., Girod,

C. E., Weissler, J., Fitzgerald, J., Kershaw, C., Klesney-Tait, J., Mageto, Y., Shay, J. W., Ji, W., Bilguvar, K., Mane, S., Lifton, R. P., … Garcia, C. K. (2015). Exome sequencing links mutations in PARN and RTEL1 with familial pulmonary fibrosis and telomere shortening. *Nature genetics*, *47*(5), 512–517. <https://doi.org/10.1038/ng.3278>

Tsakiri, K. D., Cronkhite, J. T., Kuan, P. J., Xing, C., Raghu, G., Weissler, J. C., Rosenblatt, R. L., Shay, J. W., &

Garcia, C. K. (2007). Adult-onset pulmonary fibrosis caused by mutations in telomerase. *Proceedings of the National Academy of Sciences of the United States of America*, *104*(18), 7552–7557. <https://doi.org/10.1073/pnas.0701009104>

Liver, bone marrow and other organ dysfunction in telomeropathy related ILD - *Matthew B. McCarra, MD*

Adegunsoye, A., Kropski, J. A., Behr, J., Blackwell, T. S., Corte, T. J., Cottin, V., Glanville, A. R., Glassberg, M.

K., Griese, M., Hunninghake, G. M., Johannson, K. A., Keane, M. P., Kim, J. S., Kolb, M., Maher, T. M., Oldham, J. M., Podolanczuk, A. J., Rosas, I. O., Martinez, F. J., Noth, I., … Schwartz, D. A. (2024). Genetics and Genomics of Pulmonary Fibrosis: Charting the Molecular Landscape and Shaping Precision Medicine. *American journal of respiratory and critical care medicine*, *210*(4), 401–423. <https://doi.org/10.1164/rccm.202401-0238SO>

Alder, J. K., & Armanios, M. (2022). Telomere-mediated lung disease. *Physiological reviews*, *102*(4),

1703–1720. <https://doi.org/10.1152/physrev.00046.2021>

Al-Rahawan, M. M., Giri, N., & Alter, B. P. (2006). Intensive Immunosuppression Therapy for Aplastic

Anemia Associated with Dyskeratosis Congenita. *Int J Hematol, 83* 275-276. <https://doi.org/10.1532/IJH97.06030>

Alter, B. P., Giri, N., Savage, S. A., Peters, J. A., Loud, J. T., Leathwood, L., Carr, A. G., Greene, M. H., &

Rosenberg, P. S. (2010). Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. *British journal of haematology*, *150*(2), 179–188. <https://doi.org/10.1111/j.1365-2141.2010.08212.x>

Alter, B. P., Giri, N., Savage, S. A., & Rosenberg, P. S. (2009). Cancer in dyskeratosis congenita. *Blood*,

*113*(26), 6549–6557. <https://doi.org/10.1182/blood-2008-12-192880>

Armanios, M., & Blackburn, E. H. (2012). The telomere syndromes. *Nature reviews. Genetics*, *13*(10),

693–704. <https://doi.org/10.1038/nrg3246>

Armanios, M. Y., Chen, J. J., Cogan, J. D., Alder, J. K., Ingersoll, R. G., Markin, C., Lawson, W. E., Xie, M.,

Vulto, I., Phillips, J. A., 3rd, Lansdorp, P. M., Greider, C. W., & Loyd, J. E. (2007). Telomerase mutations in families with idiopathic pulmonary fibrosis. *The New England journal of medicine*, *356*(13), 1317–1326. <https://doi.org/10.1056/NEJMoa066157>

Borie, R., Kannengiesser, C., Antoniou, K., Bonella, F., Crestani, B., Fabre, A., Froidure, A., Galvin, L.,

Griese, M., Grutters, J. C., Molina-Molina, M., Poletti, V., Prasse, A., Renzoni, E., van der Smagt, J., & van Moorsel, C. H. M. (2023). European Respiratory Society statement on familial pulmonary fibrosis. *The European respiratory journal*, *61*(3), 2201383. <https://doi.org/10.1183/13993003.01383-2022>

Borie, R., Tabèze, L., Thabut, G., Nunes, H., Cottin, V., Marchand-Adam, S., Prevot, G., Tazi, A., Cadranel,

J., Mal, H., Wemeau-Stervinou, L., Bergeron Lafaurie, A., Israel-Biet, D., Picard, C., Reynaud Gaubert, M., Jouneau, S., Naccache, J. M., Mankikian, J., Ménard, C., Cordier, J. F., … Crestani, B. (2016). Prevalence and characteristics of TERT and TERC mutations in suspected genetic pulmonary fibrosis. *The European respiratory journal*, *48*(6), 1721–1731. <https://doi.org/10.1183/13993003.02115-2015>

Comoli, P., Basso, S., & Huanga, G. C. (2005). Intensive immunosuppression therapy for aplastic anemia

associated with dyskeratosis congenita: report of a case. *International journal of hematology*, *82*(1), 35–37. <https://doi.org/10.1532/IJH97.A10416>

Diaz de Leon, A., Cronkhite, J. T., Yilmaz, C., Brewington, C., Wang, R., Xing, C., Hsia, C. C. W., & Garcia, C.

K. (2011). Subclinical lung disease, macrocytosis, and premature graying in kindreds with telomerase (TERT) mutations. *Chest*, *140*(3), 753–763. <https://doi.org/10.1378/chest.10-2865>

Dietz, A. C., Orchard, P. J., Baker, K. S., Giller, R. H., Savage, S. A., Alter, B. P., & Tolar, J. (2011).

Disease-specific hematopoietic cell transplantation: nonmyeloablative conditioning regimen for dyskeratosis congenita. *Bone marrow transplantation*, *46*(1), 98–104. <https://doi.org/10.1038/bmt.2010.65>

Fioredda, F., Iacobelli, S., Korthof, E. T., Knol, C., van Biezen, A., Bresters, D., Veys, P., Yoshimi, A., Fagioli,

F., Mats, B., Zecca, M., Faraci, M., Miano, M., Arcuri, L., Maschan, M., O'Brien, T., Diaz, M. A., Sevilla, J., Smith, O., Peffault de Latour, R., … Dufour, C. (2018). Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita. *British journal of haematology*, *183*(1), 110–118. <https://doi.org/10.1111/bjh.15495>

Gorgy, A. I., Jonassaint, N. L., Stanley, S. E., Koteish, A., DeZern, A. E., Walter, J. E., Sopha, S. C., Hamilton,

J. P., Hoover-Fong, J., Chen, A. R., Anders, R. A., Kamel, I. R., & Armanios, M. (2015). Hepatopulmonary syndrome is a frequent cause of dyspnea in the short telomere disorders. *Chest*, *148*(4), 1019–1026. <https://doi.org/10.1378/chest.15-0825>

Jonassaint, N. L., Guo, N., Califano, J. A., Montgomery, E. A., & Armanios, M. (2013). The gastrointestinal

manifestations of telomere-mediated disease. *Aging cell*, *12*(2), 319–323. <https://doi.org/10.1111/acel.12041>

Mitchell, J. R., Wood, E., & Collins, K. (1999). A telomerase component is defective in the human disease

dyskeratosis congenita. *Nature*, *402*(6761), 551–555. <https://doi.org/10.1038/990141>

Newton, C. A., Batra, K., Torrealba, J., Kozlitina, J., Glazer, C. S., Aravena, C., Meyer, K., Raghu, G., Collard,

H. R., & Garcia, C. K. (2016). Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive. *The European respiratory journal*, *48*(6), 1710–1720. <https://doi.org/10.1183/13993003.00308-2016>

Pramanik-Jonsson, L., Borssén, M., Vonlanthen, S., Nilsson, F., & Sundin, M. (2024). Severe

Thrombocytopenia Due to Bone Marrow Failure in Children With Dyskeratosis Congenita Does Not Respond to Eltrombopag Treatment: Case Series. *Journal of pediatric hematology/oncology*, *46*(1), 57–62. <https://doi.org/10.1097/MPH.0000000000002775>

Team Telomere. (2022). Telomere Biology Disorders: Diagnosis and Management Guidelines, 2nd Edition.

*Team Telomere*. <https://teamtelomere.org/telomere-biology-disorders-diagnosis-and-management-guidelines-downloads/>

Townsley, D. M., Dumitriu, B., Liu, D., Biancotto, A., Weinstein, B., Chen, C., Hardy, N., Mihalek, A. D.,

Lingala, S., Kim, Y. J., Yao, J., Jones, E., Gochuico, B. R., Heller, T., Wu, C. O., Calado, R. T., Scheinberg, P., & Young, N. S. (2016). Danazol Treatment for Telomere Diseases. *The New England journal of medicine*, *374*(20), 1922–1931. <https://doi.org/10.1056/NEJMoa1515319>

Therapeutic considerations in patients with familial ILD - *Nicholas H. Juul, MD*

Adegunsoye, A., Morisset, J., Newton, C. A., Oldham, J. M., Vittinghoff, E., Linderholm, A. L., Strek, M. E.,

Noth, I., Garcia, C. K., Wolters, P. J., & Ley, B. (2021). Leukocyte telomere length and mycophenolate therapy in chronic hypersensitivity pneumonitis. *The European respiratory journal*, *57*(3), 2002872. <https://doi.org/10.1183/13993003.02872-2020>

Alder, J. K., & Armanios, M. (2022). Telomere-mediated lung disease. *Physiological reviews*, *102*(4),

1703–1720. <https://doi.org/10.1152/physrev.00046.2021>

Allen, D. H., Basten, A., Williams, G. V., & Woolcock, A. J. (1975). Familial hypersensitivity pneumonitis.

*The American journal of medicine*, *59*(4), 505–514. <https://doi.org/10.1016/0002-9343(75)90258-2>

Calado, R. T., Yewdell, W. T., Wilkerson, K. L., Regal, J. A., Kajigaya, S., Stratakis, C. A., & Young, N. S.

(2009). Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. *Blood*, *114*(11), 2236–2243. <https://doi.org/10.1182/blood-2008-09-178871>

Clé, D. V., Catto, L. F. B., Gutierrez-Rodrigues, F., Donaires, F. S., Pinto, A. L., Santana, B. A., Darrigo, L. G.,

Valera, E. T., Koenigkam-Santos, M., Baddini-Martinez, J., Young, N. S., Martinez, E. Z., & Calado, R. T. (2023). Effects of nandrolone decanoate on telomere length and clinical outcome in patients with telomeropathies: a prospective trial. *Haematologica*, *108*(5), 1300–1312. <https://doi.org/10.3324/haematol.2022.281808>

DeBoer, E. M., Liptzin, D. R., Humphries, S. M., Lynch, D. A., Robison, K., Galambos, C., Dishop, M. K.,

Deterding, R. R., & Weinman, J. P. (2021). Ground glass and fibrotic change in children with surfactant protein C dysfunction mutations. *Pediatric pulmonology*, *56*(7), 2223–2231. <https://doi.org/10.1002/ppul.25356>

Deterding, R., Young, L. R., DeBoer, E. M., Warburton, D., Cunningham, S., Schwerk, N., Flaherty, K. R.,

Brown, K. K., Dumistracel, M., Erhardt, E., Bertulis, J., Gahlemann, M., Stowasser, S., Griese, M., & InPedILD trial investigators (2023). Nintedanib in children and adolescents with fibrosing interstitial lung diseases. *The European respiratory journal*, *61*(2), 2201512. <https://doi.org/10.1183/13993003.01512-2022>

Dressen, A., Abbas, A. R., Cabanski, C., Reeder, J., Ramalingam, T. R., Neighbors, M., Bhangale, T. R.,

Brauer, M. J., Hunkapiller, J., Reeder, J., Mukhyala, K., Cuenco, K., Tom, J., Cowgill, A., Vogel, J., Forrest, W. F., Collard, H. R., Wolters, P. J., Kropski, J. A., Lancaster, L. H., … Yaspan, B. L. (2018). Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study. *The Lancet. Respiratory medicine*, *6*(8), 603–614. <https://doi.org/10.1016/S2213-2600(18)30135-8>

Griese, M., Kappler, M., Stehling, F., Schulze, J., Baden, W., Koerner-Rettberg, C., Carlens, J., Prenzel, F.,

Nährlich, L., Thalmeier, A., Sebah, D., Kronfeld, K., Rock, H., Ruckes, C., HCQ-study group, Wetzke, M., Seidl, E., & Schwerk, N. (2022). Randomized controlled phase 2 trial of hydroxychloroquine in childhood interstitial lung disease. *Orphanet journal of rare diseases*, *17*(1), 289. <https://doi.org/10.1186/s13023-022-02399-2>

Hoffman, T. W., van Moorsel, C. H. M., van der Vis, J. J., Biesma, D. H., & Grutters, J. C. (2023). No effect

of danazol treatment in patients with advanced idiopathic pulmonary fibrosis. *ERJ open research*, *9*(5), 00131-2023. <https://doi.org/10.1183/23120541.00131-2023>

Justet, A., Klay, D., Porcher, R., Cottin, V., Ahmad, K., Molina Molina, M., Nunes, H., Reynaud-Gaubert, M.,

Naccache, J. M., Manali, E., Froidure, A., Jouneau, S., Wemeau, L., Andrejak, C., Gondouin, A., Hirschi, S., Blanchard, E., Bondue, B., Bonniaud, P., Tromeur, C., … OrphaLung Network (2021). Safety and efficacy of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis and carrying a telomere-related gene mutation. *The European respiratory journal*, *57*(2), 2003198. <https://doi.org/10.1183/13993003.03198-2020>

Justet, A., Thabut, G., Manali, E., Molina Molina, M., Kannengiesser, C., Cadranel, J., Cottin, V., Gondouin,

A., Nunes, H., Magois, E., Tromeur, C., Prevot, G., Papiris, S., Marchand-Adam, S., Gamez, A. S., Reynaud-Gaubert, M., Wemeau, L., Crestani, B., & Borie, R. (2018). Safety and efficacy of pirfenidone in patients carrying telomerase complex mutation. *The European respiratory journal*, *51*(3), 1701875. <https://doi.org/10.1183/13993003.01875-2017>

Kellogg, D., Nambiar, A., Justice, J., Goros, M., Gelfond, J., Pascual, R., Hashmi, S., Masternak, L. P.,

Lebrasseur, N., Limper, A., Kritchevsky, S., Musi, N., Tchkonia, T., & Kirkland, J. (2023). Post hoc pooled analyses of open-label and randomized controlled trials of senolytics dasatinib and quercetin in Idiopathic Pulmonary Fibrosis. *The European respiratory journal, 62*(67), 1399-3003. <https://doi.org/10.1183/13993003.congress-2023.OA2583>

Legendre, M., Butt, A., Borie, R., Debray, M. P., Bouvry, D., Filhol-Blin, E., Desroziers, T., Nau, V., Copin, B.,

Dastot-Le Moal, F., Héry, M., Duquesnoy, P., Allou, N., Bergeron, A., Bermudez, J., Cazes, A., Chene, A. L., Cottin, V., Crestani, B., Dalphin, J. C., … Nathan, N. (2020). Functional assessment and phenotypic heterogeneity of *SFTPA1* and *SFTPA2* mutations in interstitial lung diseases and lung cancer. *The European respiratory journal*, *56*(6), 2002806. <https://doi.org/10.1183/13993003.02806-2020>

Liu, S., Qi, Y., Ge, Y., Duplessis, T., Rowan, B. G., Ip, C., Cheng, H., Rennie, P. S., Horikawa, I., Lustig, A. J.,

Yu, Q., Zhang, H., & Dong, Y. (2010). Telomerase as an important target of androgen signaling blockade for prostate cancer treatment. *Molecular cancer therapeutics*, *9*(7), 2016–2025. <https://doi.org/10.1158/1535-7163.MCT-09-0924>

van Moorsel, C. H. M., van der Vis, J. J., & Grutters, J. C. (2021). Genetic disorders of the surfactant

system: focus on adult disease. *European respiratory review : an official journal of the European Respiratory Society*, *30*(159), 200085. <https://doi.org/10.1183/16000617.0085-2020>

National Institutes of Health Clinical Center. (2024). Low-Dose Danazol for the Treatment of Telomere

Related Diseases. *ClinicalTrials.gov, National Heart, Lung, and Blood Institute*. <https://clinicaltrials.gov/study/NCT03312400>

Newton, C. A., Zhang, D., Oldham, J. M., Kozlitina, J., Ma, S. F., Martinez, F. J., Raghu, G., Noth, I., &

Garcia, C. K. (2019). Telomere Length and Use of Immunosuppressive Medications in Idiopathic Pulmonary Fibrosis. *American journal of respiratory and critical care medicine*, *200*(3), 336–347. <https://doi.org/10.1164/rccm.201809-1646OC>

Planté-Bordeneuve, T., Gilber, O., Latinne, D., *et al*. (2020). Familial hypersensitivity pneumonitis

triggered by *Cladosporium herbarum* exposure during carpooling. *ERJ Open Res, 6:* 00233-2020. <https://doi.org/10.1183/23120541.00233-2020>

Sicre De Fontbrune, F., Jouneau, S., Cottin, V., Prevot, G., Nunes, H., Terriou, L., Marchand-Adam, S.,

Crestani, B., Bergeron, A., Marcais, A., Plessier, A., Lainey, E., Kannengiesser, C., Resche-Rigon, M., Borie, R., & The Orphalung Network. (2023). Late Breaking Abstract - Efficacy and safety of DANAZOL for pulmonary fibrosis associated with telomere related gene mutation. *The European respiratory journal, 62*(67), 1399-3003. <https://doi.org/10.1183/13993003.congress-2023.OA2580>

Townsley, D. M., Dumitriu, B., Liu, D., Biancotto, A., Weinstein, B., Chen, C., Hardy, N., Mihalek, A. D.,

Lingala, S., Kim, Y. J., Yao, J., Jones, E., Gochuico, B. R., Heller, T., Wu, C. O., Calado, R. T., Scheinberg, P., & Young, N. S. (2016). Danazol Treatment for Telomere Diseases. *The New England journal of medicine*, *374*(20), 1922–1931. <https://doi.org/10.1056/NEJMoa1515319>

University of Queensland, The. (2024). The TELO-SCOPE Study: Attenuating Telomere Attrition With

Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis. *ClinicalTrials.gov, The University of Queensland*. <https://clinicaltrials.gov/study/NCT04638517>

Zhang, D., Adegunsoye, A., Oldham, J. M., Kozlitina, J., Garcia, N., Poonawalla, M., Strykowski, R.,

Linderholm, A. L., Ley, B., Ma, S. F., Noth, I., Strek, M. E., Wolters, P. J., Garcia, C. K., & Newton, C. A. (2023). Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease. *The European respiratory journal*, *62*(5), 2300441. <https://doi.org/10.1183/13993003.00441-2023>

Lung transplant for familial ILD: Outcomes and specific considerations - *Joshua James Mooney, MD*

Courtwright, A. M., Fried, S., Villalba, J. A., Moniodis, A., Guleria, I., Wood, I., Milford, E., Mallidi, H. H.,

Hunninghake, G. M., Raby, B. A., Agarwal, S., Camp, P. C., Rosas, I. O., Goldberg, H. J., & El-Chemaly, S. (2016). Association of Donor and Recipient Telomere Length with Clinical Outcomes following Lung Transplantation. *PloS one*, *11*(9), e0162409. <https://doi.org/10.1371/journal.pone.0162409>

Faust, H. E., Golden, J. A., Rajalingam, R., Wang, A. S., Green, G., Hays, S. R., Kukreja, J., Singer, J. P.,

Wolters, P. J., & Greenland, J. R. (2017). Short lung transplant donor telomere length is associated with decreased CLAD-free survival. *Thorax*, *72*(11), 1052–1054. <https://doi.org/10.1136/thoraxjnl-2016-209897>

Hannan, S. J., Iasella, C. J., Sutton, R. M., Popescu, I. D., Koshy, R., Burke, R., Chen, X., Zhang, Y., Pilewski,

J. M., Hage, C. A., Sanchez, P. G., Im, A., Farah, R., Alder, J. K., & McDyer, J. F. (2023). Lung transplant recipients with telomere-mediated pulmonary fibrosis have increased risk for hematologic complications. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*, *23*(10), 1590–1602. <https://doi.org/10.1016/j.ajt.2023.06.014>

Leard, L. E., Holm, A. M., Valapour, M., Glanville, A. R., Attawar, S., Aversa, M., Campos, S. V., Christon, L.

M., Cypel, M., Dellgren, G., Hartwig, M. G., Kapnadak, S. G., Kolaitis, N. A., Kotloff, R. M., Patterson, C. M., Shlobin, O. A., Smith, P. J., Solé, A., Solomon, M., Weill, D., … Ramos, K. J. (2021). Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*, *40*(11), 1349–1379. <https://doi.org/10.1016/j.healun.2021.07.005>

Mackintosh, J. A., Yerkovich, S. T., Tan, M. E., Samson, L., Hopkins, P. M., & Chambers, D. C. (2021). Airway

Telomere Length in Lung Transplant Recipients. *Frontiers in immunology*, *12*, 658062. <https://doi.org/10.3389/fimmu.2021.658062>

Newton, C. A., Kozlitina, J., Lines, J. R., Kaza, V., Torres, F., & Garcia, C. K. (2017). Telomere length in

patients with pulmonary fibrosis associated with chronic lung allograft dysfunction and post-lung transplantation survival. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*, *36*(8), 845–853. <https://doi.org/10.1016/j.healun.2017.02.005>

Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J. F., Flaherty,

K. R., Lasky, J. A., Lynch, D. A., Ryu, J. H., Swigris, J. J., Wells, A. U., Ancochea, J., Bouros, D., Carvalho, C., Costabel, U., Ebina, M., Hansell, D. M., … ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis (2011). An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. *American journal of respiratory and critical care medicine*, *183*(6), 788–824. <https://doi.org/10.1164/rccm.2009-040GL>

Silhan, L. L., Shah, P. D., Chambers, D. C., Snyder, L. D., Riise, G. C., Wagner, C. L., Hellström-Lindberg, E.,

Orens, J. B., Mewton, J. F., Danoff, S. K., Arcasoy, M. O., & Armanios, M. (2014). Lung transplantation in telomerase mutation carriers with pulmonary fibrosis. *The European respiratory journal*, *44*(1), 178–187. <https://doi.org/10.1183/09031936.00060014>

Valapour, M., Lehr, C. J., Schladt, D. P., Smith, J. M., Swanner, K., Weibel, C. J., Weiss, S., & Snyder, J. J.

(2024). OPTN/SRTR 2022 Annual Data Report: Lung. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*, *24*(2S1), S394–S456. <https://doi.org/10.1016/j.ajt.2024.01.017>

Case Studies - *Christine Kim Garcia, MD, PhD, Rishi Raj, MD, Gerald J. Berry, MD, & Ann Noi Chi Leung, MD*

McCarthy, C. (1992). *All the Pretty Horses*. New York, Alfred A. Knopf.

Stock, C. J. W., & Renzoni, E. A. (2021). Telomeres in Interstitial Lung Disease. *Journal of clinical medicine*,

*10*(7), 1384. <https://doi.org/10.3390/jcm10071384>